Business
OncBioMune Announces Presentation at the 2018 AACR Annual Meeting
OncBioMune Announces Presentation at the 2018 AACR Annual Meeting.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\n\n BATON ROUGE, La., March 20, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (\"OncBioMune\" or the \"Company\"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, today announces that Dr. Jonathan Head, Chief Executive Officer at OncBioMune, will present a poster at the 2018 American Association for Cancer Research (\"AACR\") Annual Meeting taking place April 14 - 18, 2018 in Chicago, Illinois.\n The clinical trial abstract, entitled “Interim results of a phase 1a clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer therapeutic vaccine in PSA defined biochemical recurrent prostate cancer patients,” highlights the safety and efficacy of ProscaVax, the Company’s novel immunotherapeutic cancer vaccine, as evidenced through data collected in the study.  Based upon the impressive body of data from the Phase 1a portion of the study, OncBioMune is forgoing the planned 1b portion and moving into two, separate Phase 2 studies of ProscaVax for late-stage and early-stage prostate cancer, respectively. The abstract also will be published online in the 2018 Proceedings of the AACR. Details of the abstract are as follows: Session Title: Phase I Clinical Trials 2Session Date and Time: Monday Apr 16, 2018 8:00 AM - 12:00 PMSession Location: McCormick Place South, Hall A, Poster Section 42Poster Board Number: 14 Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/. About OncBioMune Pharmaceuticals, Inc. OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, based on their proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. Our lead pipeline product, ProscaVax™, has successfully completed enrollment and vaccination of the prostate cancer patients and is collecting long-term follow-up results for the 1a portion of their Phase 1a/1b clinical trial. Due to the impressive results and proven safety profile of ProscaVax™, OncBioMune is forgoing the 1b portion of the trial to advance ProscaVax™ into Phase 2 studies. A Phase 2 trial is scheduled to commence at ...